Success Metrics

Clinical Success Rate
40.0%

Based on 4 completed trials

Completion Rate
40%(4/10)
Active Trials
1(8%)
Results Posted
200%(8 trials)
Terminated
6(50%)

Phase Distribution

Ph not_applicable
2
17%
Ph phase_4
5
42%
Ph phase_1
1
8%
Ph phase_2
3
25%

Phase Distribution

1

Early Stage

3

Mid Stage

5

Late Stage

Phase Distribution11 total trials
Phase 1Safety & dosage
1(9.1%)
Phase 2Efficacy & side effects
3(27.3%)
Phase 4Post-market surveillance
5(45.5%)
N/ANon-phased studies
2(18.2%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

36.4%

4 of 11 finished

Non-Completion Rate

63.6%

7 ended early

Currently Active

1

trials recruiting

Total Trials

12

all time

Status Distribution
Active(1)
Completed(4)
Terminated(7)

Detailed Status

Terminated6
Completed4
Active, not recruiting1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
12
Active
1
Success Rate
40.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (9.1%)
Phase 23 (27.3%)
Phase 45 (45.5%)
N/A2 (18.2%)

Trials by Status

active_not_recruiting18%
terminated650%
completed433%
withdrawn18%

Recent Activity

1 active trials
Showing 5 of 12
active_not_recruitingphase_2

Pancreaze (Pancrelipase) for Patients With Pancreatic Adenocarcinoma With Cachexia and Exocrine Pancreatic Insufficiency

NCT04098237
completedphase_4

A Study to Compare US Marketed Creon Manufactured With a Modernized Process at an Alternate Manufacturing Site and Manufactured With the Approved Manufacturing Process at an Alternate Active Pharmaceutical Ingredient Site, in Participants With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis

NCT03924947
terminatedphase_4

A Study of Creon (Pancrelipase) in Resected and Non-resected Pancreatic Cancer Participants With Exocrine Pancreatic Insufficiency (EPI)

NCT03859869
completed

Special Investigation (All Cases) of LipaCreon in Patients With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis

NCT01427712
terminatedphase_4

Pancreatic Enzyme Supplementation for Celiac Disease

NCT02475369
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT04098237Phase 2

Pancreaze (Pancrelipase) for Patients With Pancreatic Adenocarcinoma With Cachexia and Exocrine Pancreatic Insufficiency

Active Not Recruiting
NCT03924947Phase 4

A Study to Compare US Marketed Creon Manufactured With a Modernized Process at an Alternate Manufacturing Site and Manufactured With the Approved Manufacturing Process at an Alternate Active Pharmaceutical Ingredient Site, in Participants With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis

Completed
NCT03859869Phase 4

A Study of Creon (Pancrelipase) in Resected and Non-resected Pancreatic Cancer Participants With Exocrine Pancreatic Insufficiency (EPI)

Terminated
NCT01427712

Special Investigation (All Cases) of LipaCreon in Patients With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis

Completed
NCT02475369Phase 4

Pancreatic Enzyme Supplementation for Celiac Disease

Terminated
NCT02985801Phase 1

PERT for Treatment of Exocrine Pancreatic Insufficiency in Patients With Unresectable Pancreatic Cancer

Terminated
NCT02372383Not Applicable

Improving Treatment of Nontuberculous Mycobacterial Infection in Cystic Fibrosis

Completed
NCT03469258Phase 2

Study of Pancreatic Enzyme Replacement on Completion of Adjuvant Chemotherapy for Resected Pancreatic Adenocarcinoma

Terminated
NCT01641341Phase 4

Irritable Bowel Syndrome Evaluation and Treatment in Primary Care

Completed
NCT02706236Phase 2

Trial of Pancreatic Enzyme Supplements (Pancrelipase) for Treating Pain in Patients With Chronic Pancreatitis

Withdrawn
NCT00744250Phase 4

Intraduodenal Aspiration Study to Assess the Bioavailability of Oral Pancrecarb® Compared to Placebo Control

Terminated
NCT00749099Not Applicable

Bioavailability of Pancreatic Enzymes in the Human Upper Intestine (Duodenum and Jejunum)

Terminated

All 12 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
12